Methods for the treatment of hepatitis B and hepatitis D infections

摘要

It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.

主权项

1. A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment an antisense oligonucleotide that targets mRNA of the HBV genome encoding the hepatitis B surface antigen (HBsAg) and catalyzes degradation of that mRNA, and at least one pharmaceutically acceptable agent selected from the group consisting of:
thymosin α1; interferon β-1a; interferon β-1b; interferon γ-1b; interferon λ1; interferon λ2; interferon λ3; pegylated interferon λ1; pegylated interferon λ2; GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one); dehydroepiandrosterone; androstenediol; and androstenetriol.